The Food and Drug Administration (FDA) requires a new drug’s manufacturer to present affirmative evidence of its efficacy and safety before it can be marketed. Because testing new drugs requires a delay between identification of an important, novel prescription...
Filed under: Public Health, Bioethics, Quality, Population Health, Featured, Drugs and Medical Technology, FDA, Drug approval, priority review, Risk Evaluation and Mitigation Strategies, breakthrough drugs